


RevoAb® Track Record

Since launching in July 2025, RevoAb® has been widely tested and proven by both commercial industries and academia. RevoAb's naturalness strategy has delivered exceptional improvements in antibody yields without disturbing affinity


USER

- Pharmaceutical Companies
- Biotech Startups & Ventures
- Reagent & Research Manufacturers
- Academia / Research Institutes



SUCCESS RATE

- Improvement Achieved
- Not Achieved



- *IgG Expression : 3-4 fold higher*
- *IgG Affinity : $K_d \approx 10^{-10}M$*
- *Similar effect observed with scFv*

This is a highly beneficial service!

Early User A

By utilizing RevoAb to optimize our antibody frameworks closer to native human antibodies, we saw a boost in productivity.

Early User B



Case Study: Early User C

We successfully increased the expression level by 7-fold, from a level that was undetectable by SDS-PAGE. Furthermore, flow cytometry evaluation using animal cells demonstrated that the binding affinity was fully maintained.

Expression Level

Binding Affinity

WT


7x

RevoAb mutant

Increase


0.12 mg / 1L culture

0.79 mg / 1L culture



CBB staining

Flow Cytometry using mammalian cells confirmed **no change in binding affinity.**




Case Study: Chiome Bioscience Inc.




All three RevoAb-designed scFv mutants demonstrated 3- to 6-fold higher expression than WT, maintaining equivalent binding affinity and reduced oligomer content.

Expression Level



Impurity Level

SEC-HPLC confirmed a **reduction in high-molecular-weight oligomers**



Binding Affinity

ELISA confirmed **retained binding affinity across all three mutants**

